NKTR-358, a Modified IL-2 Pathway Agonist for Selective Expansion of Tregs in vivo
Time: 1:30 pm
day: Day One | Track B | Morning
Details:
- Discussing the design of NKTR-358 using polymer chemistry
- Exploring NKTR-358’s mechanism of action and preclinical development
- Presenting Clinical highlights demonstrating Treg specificity and an optimal pharmacology profile for the treatment of autoimmune diseases
